Business Context and Reporting Period
This Form 8-K Current Report was filed by Outlook Therapeutics, Inc. on November 12, 2021, covering events occurring on November 8, 2021. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices located in Iselin, New Jersey. Its common stock and Series A warrants trade on The Nasdaq Stock Market LLC under the symbols OTLK and OTLKW, respectively.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the amendment of consulting agreements for two senior officers, effective November 1, 2021:
- Jeff Evanson (Chief Commercial Officer): Weekly hours increased from 20 to 30; monthly fee increased from $25,000 to $37,500.
- Terry Dagnon (Chief Operating Officer): Weekly hours increased from 20 to 30; monthly fee increased from $25,000 to $37,500.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document serves solely to disclose the terms of the amended consulting agreements, which are filed as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the full text of the amended consulting agreements in Exhibits 10.1 and 10.2 for additional terms not summarized in the report.
- Confirm the effective date of the fee increase (November 1, 2021) against payroll records or subsequent financial filings.
- Review the Company's most recent 10-Q or 10-K for baseline financial health, as this 8-K provides no liquidity or solvency data.